EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C22H22ClN5O2 |
| Net Charge | 0 |
| Average Mass | 423.904 |
| Monoisotopic Mass | 423.14620 |
| SMILES | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc21 |
| InChI | InChI=1S/C22H22ClN5O2/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14/h5-11,18H,4,12H2,1-3H3,(H,24,29)/t18-/m0/s1 |
| InChIKey | AAAQFGUYHFJNHI-SFHVURJKSA-N |
| Roles Classification |
|---|
| Biological Roles: | bromodomain-containing protein 4 inhibitor Any inhibitor of bromodomain-containing protein 4 (BRD4). apoptosis inducer Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms. GABA modulator A substance that does not act as agonist or antagonist but does affect the gamma-aminobutyric acid receptor-ionophore complex. GABA-A receptors appear to have at least three allosteric sites at which modulators act: a site at which benzodiazepines act by increasing the opening frequency of gamma-aminobutyric acid-activated chloride channels; a site at which barbiturates act to prolong the duration of channel opening; and a site at which some steroids may act. |
| Applications: | antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. GABA modulator A substance that does not act as agonist or antagonist but does affect the gamma-aminobutyric acid receptor-ionophore complex. GABA-A receptors appear to have at least three allosteric sites at which modulators act: a site at which benzodiazepines act by increasing the opening frequency of gamma-aminobutyric acid-activated chloride channels; a site at which barbiturates act to prolong the duration of channel opening; and a site at which some steroids may act. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| molibresib (CHEBI:95082) has role antineoplastic agent (CHEBI:35610) |
| molibresib (CHEBI:95082) has role apoptosis inducer (CHEBI:68495) |
| molibresib (CHEBI:95082) has role bromodomain-containing protein 4 inhibitor (CHEBI:137114) |
| molibresib (CHEBI:95082) is a aromatic ether (CHEBI:35618) |
| molibresib (CHEBI:95082) is a monochlorobenzenes (CHEBI:83403) |
| molibresib (CHEBI:95082) is a secondary carboxamide (CHEBI:140325) |
| molibresib (CHEBI:95082) is a triazolobenzodiazepine (CHEBI:35501) |
| IUPAC Name |
|---|
| 2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide |
| INNs | Source |
|---|---|
| molibresib | WHO MedNet |
| molibresibum | WHO MedNet |
| molibresib | WHO MedNet |
| molibrésib | WHO MedNet |
| Synonyms | Source |
|---|---|
| GSK525762A | ChEBI |
| GSK-525762A | ChEBI |
| GSK525762 | ChEBI |
| GSK 525762A | ChEBI |
| I-BET762 | ChEBI |
| I-BET 762 | DrugBank |
| Manual Xrefs | Databases |
|---|---|
| LSM-6334 | LINCS |
| DB16239 | DrugBank |
| HMDB0244491 | HMDB |
| D11326 | KEGG DRUG |
| EAM | PDBeChem |
| Registry Numbers | Sources |
|---|---|
| CAS:1260907-17-2 | KEGG DRUG |
| Citations |
|---|